Novo Nordisk A/S has detected that the insulin cartridge holder in a small number of NovoPen Echo® and/or NovoPen® 5 batches may crack or break if exposed to certain chemicals, for example certain cleaning agents. NovoPen Echo® and NovoPen® 5 are used by people with diabetes to inject their insulin.
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 40,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
The purpose of this website is to inform healthcare professionals and members of the general public about Novo Nordisk and their products.
Information placed on this website is not intended as a substitute for consultation with your healthcare professional.
Date of preparation: July 2017
NovoPen®, NovoPen Echo® and the Apis bull logo are registered trademarks of Novo Nordisk A/S
Novo Nordisk cannot provide individual medical advice to the general public. For these type of queries individuals should contact their doctor, nurse or pharmacist.
Adverse reactions should be reported to Novo Nordisk on 1850 665 665 or by email to email@example.com.
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: firstname.lastname@example.org.